Janus Capital Management LLC lowered its position in shares of Masimo Corporation (NASDAQ:MASI) by 98.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,043 shares of the medical equipment provider’s stock after selling 2,672,248 shares during the period. Janus Capital Management LLC owned approximately 0.06% of Masimo Corporation worth $2,895,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Caxton Associates LP bought a new stake in shares of Masimo Corporation during the first quarter valued at approximately $466,000. Metropolitan Life Insurance Co. NY increased its stake in shares of Masimo Corporation by 141.6% in the first quarter. Metropolitan Life Insurance Co. NY now owns 69,170 shares of the medical equipment provider’s stock valued at $6,451,000 after buying an additional 40,536 shares during the period. Paloma Partners Management Co increased its stake in shares of Masimo Corporation by 134.3% in the first quarter. Paloma Partners Management Co now owns 24,543 shares of the medical equipment provider’s stock valued at $2,288,000 after buying an additional 14,068 shares during the period. AQR Capital Management LLC increased its stake in shares of Masimo Corporation by 0.3% in the first quarter. AQR Capital Management LLC now owns 137,695 shares of the medical equipment provider’s stock valued at $12,841,000 after buying an additional 462 shares during the period. Finally, BlueCrest Capital Management Ltd bought a new stake in shares of Masimo Corporation during the first quarter valued at approximately $256,000. Institutional investors own 84.39% of the company’s stock.
Shares of Masimo Corporation (NASDAQ MASI) traded up 1.88% during trading on Friday, hitting $83.58. 604,908 shares of the stock traded hands. The company has a 50-day moving average of $92.27 and a 200-day moving average of $89.85. The firm has a market cap of $4.34 billion, a P/E ratio of 13.70 and a beta of 0.80. Masimo Corporation has a 52 week low of $53.78 and a 52 week high of $104.71.
Masimo Corporation (NASDAQ:MASI) last posted its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.12. The company had revenue of $192.90 million during the quarter, compared to the consensus estimate of $189.03 million. Masimo Corporation had a return on equity of 23.45% and a net margin of 45.90%. The firm’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.57 EPS. On average, analysts forecast that Masimo Corporation will post $2.80 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Masimo Corporation (NASDAQ:MASI) Position Decreased by Janus Capital Management LLC” was reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/08/12/masimo-corporation-nasdaqmasi-stake-reduced-by-janus-capital-management-llc-updated-updated-updated.html.
MASI has been the topic of several research analyst reports. Zacks Investment Research downgraded shares of Masimo Corporation from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 11th. Roth Capital raised their target price on shares of Masimo Corporation from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, July 19th. Wedbush restated an “outperform” rating and set a $112.00 target price on shares of Masimo Corporation in a report on Monday, May 22nd. Stifel Nicolaus initiated coverage on shares of Masimo Corporation in a report on Monday, July 10th. They set a “buy” rating and a $105.00 target price on the stock. Finally, BidaskClub upgraded shares of Masimo Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $94.00.
In related news, Director Sanford Fitch sold 6,000 shares of the stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $91.89, for a total transaction of $551,340.00. Following the sale, the director now owns 89,249 shares of the company’s stock, valued at approximately $8,201,090.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jon Coleman sold 25,000 shares of the firm’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $97.50, for a total value of $2,437,500.00. Following the completion of the sale, the insider now directly owns 32,201 shares in the company, valued at approximately $3,139,597.50. The disclosure for this sale can be found here. Insiders have sold a total of 115,000 shares of company stock valued at $10,773,180 in the last quarter. 16.60% of the stock is owned by corporate insiders.
Masimo Corporation Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
What are top analysts saying about Masimo Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Masimo Corporation and related companies.